StockData
AbbVie Inc. logo

AbbVie Inc.

ABBVNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 3, 2026Score 10/3089% above fair value
$288.84−6.05 (-2.05%)

Close on Nov 2, 2026Market cap $510.41BP/E 81.6Yield 2.30%

AbbVie Venclexta (venetoclax) by Quarter

Venclexta (venetoclax) — International operational (constant-currency) growth YoY (%) (%)

QuarterlyAnnual

AbbVie Venclexta (venetoclax): 5.0% in Q2 2026, down 4.1 pts from a year earlier. That is the lowest of the 25 quarters on record here.

Latest, Q2 2026
5.0%
Period ended Jun 30, 2026
Change on a year earlier
-4.1 pts
9.1% in Q2 2025
History
25 quarters
Since Q2 2020
Sources
25
Documents cited below

Where the Q2 2026 figure comes from

“|| Venclexta | 369 | 402 | 771 | 14.8 | 8.8 | 11.6 | 5.0 | 9.6”

Source: Form 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗

Reported in Form 8-K Key Product Revenues Schedule.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVenclexta (venetoclax) — International operational (constant-currency) growth YoY (%) (%)Year on yearSource
Q2 2026Jun 30, 20265.0%-4.1 ptsForm 8-K (abbv-20260630xexhibit991.htm, filed 2026-07-31) ↗
Q1 2026Mar 31, 202610.1%-3.3 ptsForm 8-K (abbv-20260331xexhibit991.htm, filed 2026-04-29) ↗
Q4 2025Dec 31, 20256.6%-6.6 ptsForm 8-K (abbv-20251231xexhibit991.htm, filed 2026-02-04) ↗
Q3 2025Sep 30, 202510.0%-5.4 ptsForm 8-K (abbv-20250930xexhibit991.htm, filed 2025-10-31) ↗
Q2 2025Jun 30, 20259.1%-9.3 ptsForm 8-K (abbv-20250630xexhibit991.htm, filed 2025-07-31) ↗
Q1 2025Mar 31, 202513.4%-12.7 ptsForm 8-K (abbv-20250331xexhibit991.htm, filed 2025-04-25) ↗
Q4 2024Dec 31, 202413.2%-11.9 ptsForm 8-K (abbv-20241231xexhibit991.htm, filed 2025-01-31) ↗
Q3 2024Sep 30, 202415.4%-4.5 ptsForm 8-K (abbv-20240930xexhibit991.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 202418.4%-6.5 ptsForm 8-K (abbv-20240630xexhibit991.htm, filed 2024-07-25) ↗
Q1 2024Mar 31, 202426.1%+6.9 ptsForm 8-K (abbv-20240331xexhibit991.htm, filed 2024-04-26) ↗
Q4 2023Dec 31, 202325.1%+8.1 ptsForm 8-K (abbv-20231231xexhibit991.htm, filed 2024-02-02) ↗
Q3 2023Sep 30, 202319.9%+6.7 ptsForm 8-K (abbv-20230930xexhibit991.htm, filed 2023-10-27) ↗
Q2 2023Jun 30, 202324.9%-4.4 ptsForm 8-K (abbv-20230630xexhibit991.htm, filed 2023-07-27) ↗
Q1 2023Mar 31, 202319.2%-26.0 ptsForm 8-K (abbv-20230331xexhibit991.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 202217.0%-36.5 ptsForm 8-K (abbv-20221231xexhibit991.htm, filed 2023-02-09) ↗
Q3 2022Sep 30, 202213.2%-56.3 ptsForm 8-K (abbv-20220930xexhibit991.htm, filed 2022-10-28) ↗

Cite this data

StockData. (2026). AbbVie Venclexta (venetoclax) (%), quarterly Q2 2020–Q2 2026 [Data set]. Compiled from AbbVie SEC filings and investor materials. https://stockdatahq.com/stocks/abbv/kpis/venclexta-intl-op-yoy

See every metric in the AbbVie KPI table. Data updated Oct 26, 2026.